作者:Xinyi Song、Xiaohai Li、Claudia H. Ruiz、Yan Yin、Yangbo Feng、Theodore M. Kamenecka、Michael D. Cameron
DOI:10.1016/j.bmcl.2011.12.125
日期:2012.2
shown to have overlapping substrate and inhibitor profiles and their inhibition has been demonstrated to be involved in numerous pharmacokinetic drug–drug interactions. Here we report the first highly selective CYP3A4 inhibitor optimized from an initial lead with ≈30-fold selectivity over CYP3A5 to yield a series of compounds with greater than 1000-fold selectivity.
细胞色素 P450 是负责药物和异生素氧化代谢的主要酶家族。CYP3A4 和 CYP3A5 已被证明具有重叠的底物和抑制剂谱,并且它们的抑制作用已被证明与许多药代动力学药物相互作用有关。在这里,我们报告了第一个高选择性 CYP3A4 抑制剂,该抑制剂从初始先导物优化,选择性比 CYP3A5 高 30 倍,以产生一系列选择性大于 1000 倍的化合物。